Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00836537 · ClinicalTrials.gov registry record · Phase 1
Benazepril HCl 40 mg Tablets, Fed
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00836537: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00836537 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00836537, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 40 mg Benazepril Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 40 mg LOTENSIN® Tablets by Novartis Pharmaceuticals following a single oral dose (1 x 40 mg) in healthy adult volunteers under non-fasting conditions.
Interventions
- DRUG Benazepril HCl 40 mg Tablets
- DRUG Lotensin® 40 mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2001-03 |
| Est. Completion | 2001-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00836537
The ClinicalTrials.gov registry entry for NCT00836537 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Benazepril HCl 40 mg Tablets is the first listed.
NCT00836537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00836537 about?
NCT00836537 is a clinical study titled "Benazepril HCl 40 mg Tablets, Fed". This study will compare the relative bioavailability (rate and extent of absorption) of 40 mg Benazepril Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 40 mg LOTENSIN® Tablets by Novartis Pharmaceuticals following a single oral dose (1 x 40 mg) in healthy adult volunteer...
What is the current status of trial NCT00836537?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2001-03. Estimated completion is 2001-03.
What interventions are being tested in trial NCT00836537?
The interventions under investigation include: Benazepril HCl 40 mg Tablets (DRUG), Lotensin® 40 mg Tablets (DRUG).
Who is sponsoring clinical trial NCT00836537?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.